Reply to Comments on HIPEC for Granulosa Cell Tumors
Author Information
Author(s): Luis Felipe Falla-Zuniga, Armando Sardi, Mary Caitlin King, Vadim Gushchin
Primary Institution: Mercy Medical Center, Baltimore, MD, USA
Conclusion
CRS/HIPEC is a feasible therapeutic option for recurrent granulosa cell tumors, despite mixed survival outcomes.
Supporting Evidence
- One patient remains disease-free 58.7 months after treatment.
- Another patient had a recurrence but is currently disease-free after additional treatment.
- One patient died due to complications without recurrence.
Takeaway
The study looked at three patients with a specific type of ovarian tumor who had surgery and a special treatment. One is doing well, one had a recurrence but is okay now, and one sadly passed away.
Methodology
The study involved three patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Limitations
The small sample size limited the ability to perform Kaplan–Meier survival analysis.
Participant Demographics
All participants had granulosa cell tumors and underwent CRS/HIPEC.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website